癌症輔助治療

INT-coriolus-versicolor-001 3 個適應症被研究

B 1 C 2

適應症與證據等級

癌症輔助治療 Cancer Adjunct Therapy

B 🟡 B 初步證據證據分歧 🚨 高市場風險

→

免疫功能 Immune Function

C 🟠 C 薄弱證據已發布 🚨 高市場風險

→

疲勞 Fatigue

C 🟠 C 薄弱證據已發布 ⚠️ 中度市場風險

→

法規與權威立場 (L4)

L4a · US FDA

立場：cautious

Turkey tail are known to have anti-cancer, antiviral, antibacterial and antifungal effects as well as immune modulating effects. ... The claims on your website establish that your products are drugs under section 201(g)(1)(B) of the FD&C Act because they were intended for use in the cure, mitigation, treatment, or prevention of disease.

來源 ↗

L4b · EU EFSA

立場：against

Commission Implementing Decision of 6 December 2021 (C(2021) 8744 final) terminating the procedure for authorising the placing on the market within the Union of the novel food 'Coriolus versicolor' without updating the Union list of novel foods pursuant to Regulation (EU) 2015/2283.

來源 ↗

L4c · UK NHS

立場：not_addressed

L4d · TW TFDA / 衛福部

立場：neutral

L4e · WHO

立場：not_addressed

市場與行銷 (L10)

L10a · TW Market Channels

雲芝多醣 PSP 膠囊 NT$2,800

L10b · TW Legal Identity (TFDA)

雲芝菌絲體得供食品使用

L10c · TW Community (PTT/Dcard/Mobile01)